The number of biopharma M&A deals announced so far this year is higher than the yearly average for the last 15 years, while deal value has already eclipsed last year’s…
Intellia Therapeutics has temporarily paused dosing and screening in a pair of phase 3 trials in response to a liver safety signal. Shares in Intellia fell 44% to $14.34 in…
Zenas Biopharma’s autoimmune drug candidate has been tied to a 95% reduction in a type of brain lesions over 12 weeks in a phase 2 multiple sclerosis (MS) study. The…
MapLight Therapeutics is heading to the Nasdaq this morning via a $250 million IPO the biotech will use to advance its challenger to Bristol Myers Squibb’s schizophrenia med Cobenfy. The…
BridgeBio has vaulted over the success bar it set for a phase 3 rare disease trial, linking the candidate to significant improvements on biomarker and clinical outcomes to tee up…
Fresh from a European cancer conference that was all about antibody-drug conjugates, GSK has turned to French biotech Syndivia for a preclinical prostate cancer prospect. Syndivia’s ADC has already proven…
Almost a year after buying Kate Therapeutics, Novartis has scooped up another San Diego-based muscle dystrophy biotech in one of the biggest acquisitions of 2025 so far. The Swiss pharma…
Just as Adverum’s cash reserves were running dry, Eli Lilly has swooped in to buy the biotech and its phase 3-stage eye disease gene therapy. The prize for Lilly is…
With a $157 million series C funding round, Hemab Therapeutics is looking to infuse innovation into the treatment landscape for rare and underserved bleeding disorders. The oversubscribed series C was…
Biogen plans to beef up its early-stage immunology pipeline by handing over $70 million in upfront cash for the rights to Vanqua Bio’s preclinical C5aR1 antagonist. Biogen described C5aR1 as…